• Economy
  • Editor’s Pick
Money Rise Today – Investing and Stock News
  • Investing
  • Stock
Investing

Equifax’s solid Q2 leads to price target hikes by Goldman Sachs, Baird, and Needham: Should you buy?

by July 19, 2024
written by July 19, 2024

Equifax Inc. (NYSE: EFX) delivered a robust performance in its Q2 2024 earnings, surpassing expectations and igniting a flurry of optimistic reactions from financial analysts.

Analysts at Goldman Sachs raised their target from $246 to $277, maintaining a ‘Neutral’ stance. Baird, seeing more potential, pushed their target from $260 to $290, sticking with an ‘Outperform’ rating.

Needham was even more optimistic, increasing their target from $305 to $320 and maintaining a ‘Buy’ rating. Similarly, Oppenheimer set their sights at $300, up from $272, also with an ‘Outperform’ rating.

Q2 earnings

This flurry of adjustments followed the announcement of Equifax’s Q2 earnings on July 17, 2024, which revealed a Non-GAAP EPS of $1.82, surpassing expectations by $0.09.

The reported revenue of $1.43 billion, though in line with forecasts, underscored an 8.3% year-over-year growth. Notably, U.S. mortgage revenue grew 4% despite a 13% decline in USIS mortgage credit inquiries, underscoring resilience in a tough mortgage market.

The Workforce Solutions segment reported a 5% revenue increase, bolstered significantly by a 20% jump in Verification Services non-mortgage revenue, primarily driven by government and talent solutions.

Moreover, international revenue saw a robust 17% growth in reported terms and an even more impressive 28% on a local currency basis, with organic growth clocking in at 12%.

Equifax’s strategic utilization of its new EFX Cloud platform has evidently paid dividends.

The platform hosted 89% of new models and scores built using Artificial Intelligence and Machine Learning, marking a significant leap in product innovation, as reflected by a 12.5% new product Vitality Index for the quarter.

These innovations are part of Equifax’s broader EFX2026 strategic priorities, which aim to bolster the company’s long-term revenue and operational efficiency.

Outlook and valuation

Equifax reiterated its full-year 2024 guidance with a revenue midpoint expectation of $5.720 billion, representing an 8.6% increase, and an adjusted EPS of $7.35.

This guidance takes into account the projected 11% decline in 2024 U.S. mortgage credit inquiries, paralleling the reduction in cloud spending, which is expected to further drive cost savings and profitability.

Despite these robust figures, a few analysts believe that Equifax might be overvalued.

They point out that this ongoing high valuation is driven by market momentum and optimism, despite a backdrop of high mortgage rates and potentially overstated economic strength.

However, Equifax’s ability to maintain strong revenue growth, particularly in non-mortgage areas which make up roughly 80% of its revenue, provides a counter-narrative to concerns about overvaluation.

Looking at the broader picture, Equifax’s operational adjustments and cloud infrastructure enhancements have positioned it well for future scalability and efficiency.

The company’s push towards more innovative and data-driven solutions, particularly in government and talent solutions, is likely to sustain its revenue growth trajectory.

With the fundamentals scrutinized and the company’s growth trajectory outlined, the stage is set for us to pivot our analysis.

Let’s turn our attention to the stock’s charts to see if the upward momentum in fundamentals is mirrored in Equifax’s price trajectory, providing us with a clearer picture of its potential as an investment.

Closing above $271.5 critical

Although Equifax’s stock has surged more than 60% since November last year, it still trades below its all-time high above $300 made at the end of 2022.

If we draw a trendline from that peak (displayed in the chart) we can find that it briefly breached above it yesterday after the Q2 earnings release but retraced immediately.

EFX chart by TradingView

For bullish investors, this should be a cause of concern. Despite the overall bullish trend across timeframes, one shouldn’t initiate a long position unless the stock gives a decisive daily closing above this bearish trendline which currently lies near $271.5.

Traders who have a bearish outlook must also refrain from shorting the stock at current levels and wait for it to undergo some retracement or consolidation.

If the stock falls below its 50-day moving average, currently at $242, that will suggest short-term weakness, where one can initiate a short position.

The post Equifax’s solid Q2 leads to price target hikes by Goldman Sachs, Baird, and Needham: Should you buy? appeared first on Invezz

0 comment
0
FacebookTwitterPinterestEmail

previous post
ArcelorMittal resolves 55-day Mexican blockade with 8% pay hike and new settlement
next post
New poll reveals what Democrats think of Harris as president

related articles

Asian markets open: Nikkei, Hang Seng fall on...

June 12, 2025

Aluminum and steel tariffs spark rise in secondary...

June 12, 2025

Airbus sees aviation boom ahead, global fleet to...

June 12, 2025

US-China trade talks and Washington’s decade-long effort to...

June 12, 2025

Europe markets open: Stoxx 600 dips as UK...

June 12, 2025

UK GDP falls by 0.3% in April as...

June 12, 2025

Gordon Brothers buys Poundland; pledges £80 mn for...

June 12, 2025

Air India plane crash: London-bound flight with 242...

June 12, 2025

Air India plane crash live update: Indian President...

June 12, 2025

Copper remains supported for now even as China...

June 12, 2025
Enter Your Information Below To Receive Free Trading Ideas, Latest News, And Articles.


Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!

Latest News

  • Trump directs agencies to follow Supreme Court rulings, as he continues to rein in administrative state

    April 15, 2025
  • OpenAI to release web browser in challenge to Google Chrome

    July 10, 2025
  • On 9/11 anniversary Afghan opposition leader warns country once again a ‘safe haven for terrorists’

    September 11, 2024
  • Marco Rubio confirmed by Senate to be next secretary of state, becomes first Trump cabinet pick to be approved

    January 21, 2025
  • ‘Absurd’: White House blasts law firm that helped fuel Russia hoax after challenging Trump order

    March 13, 2025

Popular Posts

  • 1

    Secret Service admits leaning on ‘state and local partners’ after claim it ignored Trump team’s past requests

    July 21, 2024
  • 2

    Elon and Vivek should tackle US funding for this boondoogle organization and score a multimillion dollar win

    December 4, 2024
  • 3

    Five more House Democrats call on Biden to drop out, third US senator

    July 19, 2024
  • 4

    Forex Profit Calculator: Maximize Your Trading Potential

    July 10, 2024
  • 5

    Biden calls to ‘lower the temperature’ then bashes Trump in NAACP speech

    July 17, 2024

Categories

  • Economy (829)
  • Editor's Pick (5,319)
  • Investing (634)
  • Stock (841)

Latest Posts

  • Long UPST: Upstart Holdings Q3 Results Spark Optimism Amid Strong Growth and Bullish Market Reaction

    December 4, 2024
  • Blinken postpones Middle East visit over security concerns, anticipated Iranian retaliation

    August 13, 2024
  • Trump praises Elon Musk as ‘patriot, a brilliant guy, and a friend of mine’ amid DOGE exit

    April 24, 2025

Recent Posts

  • Ethereum price is on the rise for the seventh day in a row

    July 15, 2024
  • Trump remains committed to US owning Gaza, says Middle East states could help rebuild war-torn area

    February 10, 2025
  • Trump super PAC launches $50m battleground state ad blitz to make ‘final pitch’ to voters

    October 31, 2024

Editor’s Pick

  • NSA investigates ‘secret sex chats’ under guise of DEI on internal agency message board

    February 25, 2025
  • Trump nominates Mike Huckabee for US ambassador to Israel

    November 12, 2024
  • President Trump takes on ‘Big Pharma’ by signing executive order to lower drug prices

    May 12, 2025
  • About us
  • Contacts
  • Privacy Policy
  • Terms & Conditions

Disclaimer: moneyrisetoday.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

Copyright © 2025 moneyrisetoday.com | All Rights Reserved

Money Rise Today – Investing and Stock News
  • Economy
  • Editor’s Pick
Money Rise Today – Investing and Stock News
  • Investing
  • Stock